Hyperspectral Imaging

Spectraserve deploys the power of hyperspectral imaging combined with real time data processing to help surgeons clearly identify regions of residual disease that are invisible to the naked eye

The Problem

When removing diseased tissue, such as tumor, it is often unclear where the tumor ends and the healthy tissue begins.

Leaving residual disease in the patient, known as a positive margin, leads to worse outcomes, increased cost of follow in treatments, and increases the odds of repeat operation

Visualizing the diseased tissue at the point of care would be a significant step toward improving outcomes.

The Solution

Our systems make use of the fact that all materials, including human tissue in various states of disease, have a unique "spectral fingerprint". This is because the interaction with light is determined by the underlying biophysical and biochemical properties of tissue in question. Conditions such as cancer, infection, or necrosis may or may not appear similar to the naked eye, but the cell level changes of the disease process change how certain wavelengths of light interface with the tissue.

The Horus System is able to sample an extremely large range of the electromagenetic spectrum with ultra-high precision, allowing for detection of these unique spectral fingerprints.

This precise sampling allows us to differentiate between healthy and diseased tissue across a wide range of tissue types and disease states.

Combined with powerful software, we make these results available to clinician's in real time, delivering new insights right at the point of care.

The Results

We have demonstrated accurate detection of a range of disease from excised human tissue samples.

As compared to histopathology, our approach makes the results available in real time and without the need for tissue processing

As compared to specimen radiography, we demonstrate clear detection regions of disease, not just surrogate markers like microcalcifications.